35219-13-7

Basic information

• Product Name: 4-(1,3,4-OXADIAZOL-2-YL)ANILINE
• Synonyms: 4-(1,3,4-OXADIAZOL-2-YL)ANILINE;BUTTPARK 145\50-07;2-(4-Aminophenyl)-1,3,4-oxadiazole;4-(1,3,4-oxadiazol-2-yl)benzenaMine;4-[1,3,4]Oxadiazol-2-yl-phenylamine
• CAS NO: 35219-13-7
• Molecular Formula: C₈H₇N₃O
• Molecular Weight: 161.16
• Mol File: 35219-13-7.mol
• Article Data: 6

Chemical Properties

• Melting Point: 137-139°
• Boiling Point: 336.1±44.0 °C(Predicted)
• Appearance: /
• Density: 1.276±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 2.32±0.10(Predicted)
• CAS DataBase Reference: 4-(1,3,4-OXADIAZOL-2-YL)ANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(1,3,4-OXADIAZOL-2-YL)ANILINE(35219-13-7)
• EPA Substance Registry System: 4-(1,3,4-OXADIAZOL-2-YL)ANILINE(35219-13-7)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 35219-13-7(Hazardous Substances Data)

Usage

Description

4-(1,3,4-OXADIAZOL-2-YL)ANILINE is an organic compound that features a core structure of oxadiazole, which is a five-membered ring containing two nitrogen atoms and one oxygen atom. 4-(1,3,4-OXADIAZOL-2-YL)ANILINE is known for its potential applications in various fields, particularly in the development of pharmaceuticals and materials science.

Uses

Used in Pharmaceutical Industry:
4-(1,3,4-OXADIAZOL-2-YL)ANILINE is used as a reagent for the preparation of fused heterocyclic derivatives. These derivatives are of significant interest due to their potential as anticancer agents. 4-(1,3,4-OXADIAZOL-2-YL)ANILINE's unique structure allows for the development of new drugs that can target and combat cancer cells effectively.
Application Reason:
The use of 4-(1,3,4-OXADIAZOL-2-YL)ANILINE in the pharmaceutical industry is primarily driven by its ability to form fused heterocyclic derivatives with potential anticancer properties. These derivatives can be further modified and optimized to enhance their therapeutic effects, making them valuable candidates for the development of novel cancer treatments.

Upstream product

• 4291-13-8 2-(4-nitrophenyl)-1,3,4-oxadiazole 
• 122-51-0 orthoformic acid triethyl ester 
• 5351-17-7 4-aminobenzohydrazide 
• 619-45-4 4-methoxycarbonyl aniline 
• 149-73-5 trimethyl orthoformate 
• 1895-39-2 sodium chlorodifluoroacetate 
• 619-50-1 4-nitrobenzoic acid methyl ester 
• 618-94-0 3-nitrobenzoic acid hydrazide 
• 636-97-5 N-amino-(4-nitrophenyl)carboxamide 
• 5565-72-0 2-(3-nitrobenzene)-1,3,4-oxadiazole 
• 150-13-0 4-amino-benzoic acid 

Downstream Products

• 6336-70-5 4-(4-aminobenzenesulfonylamino)benzoic acid 
• 1438423-94-9 (R)-2-(6-(4-(1,3,4-oxadiazol-2-yl)phenylamino)-5-cyanopyrazin-2-ylamino)butanamide 
• 1071691-56-9 4-acetylamino-N-(4-[1,3,4]oxadiazol-2-yl-phenyl)-benzenesulfonamide 
• 92906-14-4 4-nitro-N-(4-[1,3,4]oxadiazol-2-yl-phenyl)-benzenesulfonamide 

Relevant articles and documents

Discovery of a Potent Glutathione Peroxidase 4 Inhibitor as a Selective Ferroptosis Inducer

Potent and selective ferroptosis regulators promote an intensive understanding of the regulation and mechanisms underlying ferroptosis, which is highly associated with various diseases. In this study, through a stepwise structure optimization, a potent and selective ferroptosis inducer was developed targeting to inhibit glutathione peroxidase 4 (GPX4), and the structure-activity relationship (SAR) of these compounds was uncovered. Compound26aexhibited outstanding GPX4 inhibitory activity with a percent inhibition up to 71.7% at 1.0 μM compared to 45.9% of RSL-3. At the cellular level,26acould significantly induce lipid peroxide (LPO) increase and effectively induce ferroptosis with satisfactory selectivity (the value of 31.5). The morphological analysis confirmed the ferroptosis induced by26a. Furthermore,26asignificantly restrained tumor growth in a mouse 4T1 xenograft model without obvious toxicity.

THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1 comprising administering to a subject in need thereof a compound described here.

HYDRAZONE DERIVATIVE

A compound represented by the following formula (I): wherein R1 represents hydrogen, aryl which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent, etc.; R2 represents hydrogen, aryl which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent, etc.; R3 represents hydrogen, etc.; Ar represents a divalent group derived from aromatic hydrocarbon, etc.; X represents a single bond, linear or branched alkylene having from 1 to 3 carbon atoms which may have a substituent, etc.; and G represents halogen, a saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent, etc., a salt thereof or a solvate thereof; and an agent for inhibiting aggregation and/or deposition of an amyloid protein or an amyloid-like protein, which comprises the compound, a salt thereof or a solvate thereof